Analysis and quantification of microRNAs in prostate tumors

Not Applicable

Completed

• Conditions: Prostate cancer; Cancer; Malignant neoplasm of prostate

• Registration Number: ISRCTN67055660
• Lead Sponsor: The Foundation for Research in Urology [Fundación para la Investigación en Urología (FIU)] (Spain)

Brief Summary

1. Circulating miR-337-3p as a novel biomarker for prostate cancer. Manuel Valladares Ayerbes1, Vanessa Medina Villaamil2, Sara Martinez Breijo3, Isabel Santamarina Cainzos2, Guadalupe Aparicio2, Jose Gonzalez Dacal3, Paula Portela Pereira3, Dario Vazquez Pazos3, Francisco Gomez-Veiga3, Luis M. Antón Aparicio1, 4. 1-Medical Oncology Service, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; 2-Biomedical Research Institute, A Coruña, Spain; 3-Urology Service, CHU A Coruña, A Coruña, Spain; 4-Medical Department, UDC, A Coruña, Spain. Accepted as Poster presentation for the 2013 ASCO Annual Meeting (May 31 - June 4, 2013) 2. MicroRNAs as emerging biomarkers for micrometastasis detection in prostate tumors. Francisco Gómez Veiga1, Vanessa Medina Villaamil2, Sara Martínez Breijo1, Isabel Santamarina Cainzos2, Jose González Dacal1, Paula Portela Pereira2, Darío Vázquez Pazos1, María Quindós Varela3, Manuel Valladares Ayerbes3, Luis Antón Aparicio3, 4. 1-Urology Service, CHU A Coruña, A Coruña, Spain; 2- Biomedical Research Institute, A Coruña, Spain; 3- Medical Oncology Service, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; 4- Medical Department, UDC, A Coruña, Spain. Accepted as Poster presentation for AUA 2013, (San Diego, May 2013) 3. The microRNA profile of prostate carcinoma risk groups obtained by SYBR-green-based miARN RT-qPCR arrays.V Medina Villaamil, S Martínez Breijo, F Gómez Veiga, J Ponce Díaz-Reixa, JA González Dacal, V Chantada Abal, I Santamarina Caínzos, G Aparicio Gallego, LM Antón Aparicio. Presented as Poster at Systems Biology, Select Biosciences. Madrid, Spain. October 2012 4. Papel de los microARNs como biomarcadores de detección de micrometástasis en tumores de próstata. Martínez Breijo, S; Medina Villaamil, V; Ponce Díaz-Reixa, J; Gonzalez Dacal, J; Santamarina Cainzos, I; Blanco Castro, E; Pertega, S; Casas Nebra, J; Zarraonandía Andraca, A; Antón Aparicio, L; Gómez Veiga, F; Chanatada Abal, V. Presented as Poster at LXXVII Congreso Nacional de Urología. Vigo, Spain. June 2012. 5. Análisis de microARNs circulantes como biomarcadores de detección de micrometástasis en tumores de próstata. Martínez Breijo, S; Medina Villaamil, V; Ponce Díaz-Reixa, J; González Dacal, J; Santamarina Caínzos, I; Portela Pereira, P; Blanco Castro, E; Pertega, S; Casas Nebra, J; Zarraonandía Andraca, A; Antón Aparicio, L; Gómez Veiga, F; Chantada Abal, V. Presented as Oral comunication at XXII Congreso de la Sociedad Gallega de Urología. Lugo, Spain. May 2012

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-05-28
• Study Completion: 2015-06-30
• Last Update Posted: 14 September 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 162

Inclusion Criteria

1. Patients with pathological diagnosis confirmed of localized, locally advanced or metastatic prostate cancer according to the TNM (tumor, lymph nodes, metastasis) classification, NCCN (National Comprehensive Cancer Network), during the period of study
2. Older than 18 years
3. Patients with signed informed consent

Exclusion Criteria

1. Patients with a history of epithelial cancer, except skin carcinoma correctly treated
2. Patients who are receiving systemic cancer treatment
3. Thrombocytopenia less than 20,000 /ml or coagulopathies not medically controlled

Study & Design

• Study Type: Observational
• Study Design: Not specified